Most Read Articles
Pearl Toh, 10 Oct 2019
Adding a LAMA* to the double combination therapy of ICS** plus LABA*** in a single inhaler improves lung function and reduces exacerbations in patients whose asthma is inadequately controlled with the combination treatment, according to the TRIMARAN and TRIGGER# studies presented at ERS 2019.
Yesterday
Environmental quality and exposure to pollution may play a small part in the development of metabolic diseases, such as diabetes, a new study has found.
Tristan Manalac, 3 days ago
Sleep deprivation impairs adolescents’ long-term retention of classroom material, according to a recent Singapore study.
5 days ago
Eating alone may help in weight management as findings of a recent study suggest that eating with friends lead to higher food intake.

Cabozantinib not superior to mitoxantrone-prednisone for pain relief in mCRPC

24 May 2019

Cabozantinib is not better than mitoxantrone-prednisone at relieving pain in patients with metastatic castration-resistant prostate cancer (mCRPC) with symptomatic bone metastasis, a recent study suggests.

Researchers randomly assigned 119 mCRPC patients to receive 60 mg oral cabozantinib once-daily (n=61; median age, 65.0 years) or 12 mg/m2 mitoxantrone every 3 weeks with 5 mg oral prednisone twice-daily (n=58; median age, 66.0 years). Six-week pain response, measured using the Brief Pain Inventory and validated at week 12, was the primary efficacy endpoint.

In the intention-to-treat population, no significant difference in pain response was observed between the cabozantinib and mitoxantrone-prednisone groups (15 percent vs 17 percent; difference, –2 percent; 95 percent CI, –16 to 11; p=0.8). The same trend was obtained when pain scores were considered as continuous variables (difference between the means, 4.6 percent; –7.8 to 17).

However, bone scan response was significantly greater in patients who received cabozantinib (31 percent vs 5.2 percent; difference, 26 percent; 13–39).

There were no significant between-group differences observed in median overall survival (cabozantinib vs mitoxantrone-prednisone: 9.0 vs 7.9 months; stratified hazard ratio [HR], 0.70; 0.44–1.10) and progression-free survival (2.9 vs 2.8 months; stratified HR, 0.74; 0.41–1.34).

All patients experienced at least one adverse event (AE). Grade 3/4 AEs were common in either group: 70 percent for the cabozantinib and 67 percent for the mitoxantrone-prednisone groups. A similar pattern was observed for serious AEs, which were present in 72 percent and 61 percent of patients in the respective groups.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 10 Oct 2019
Adding a LAMA* to the double combination therapy of ICS** plus LABA*** in a single inhaler improves lung function and reduces exacerbations in patients whose asthma is inadequately controlled with the combination treatment, according to the TRIMARAN and TRIGGER# studies presented at ERS 2019.
Yesterday
Environmental quality and exposure to pollution may play a small part in the development of metabolic diseases, such as diabetes, a new study has found.
Tristan Manalac, 3 days ago
Sleep deprivation impairs adolescents’ long-term retention of classroom material, according to a recent Singapore study.
5 days ago
Eating alone may help in weight management as findings of a recent study suggest that eating with friends lead to higher food intake.